Nifuroxazide, a STAT3 inhibitor, mitigates inflammatory burden and protects against diabetes-induced nephropathy in rats

被引：67
作者：
Said, Eman [1 ]
Zaitone, Sawsan A. [2 ,3 ]
Eldosoky, Mohamed [4 ]
Elsherbiny, Nehal M. [5 ,6 ]
机构：
[1] Mansoura Univ, Dept Pharmacol & Toxicol, Fac Pharm, Mansoura, Egypt
[2] Suez Canal Univ, Dept Pharmacol Toxicol, Fac Pharm, Ismailia, Egypt
[3] Univ Tabuk, Dept Pharmacol Toxicol, Fac Pharm, Tabuk, Saudi Arabia
[4] Mansoura Univ, Dept Med Physiol, Fac Med, Mansoura, Egypt
[5] Mansoura Univ, Dept Biochem, Fac Pharm, Mansoura, Egypt
[6] Univ Tabuk, Dept Pharmaceut Chem, Fac Pharm, Tabuk, Saudi Arabia
来源：
CHEMICO-BIOLOGICAL INTERACTIONS | 2018年 / 281卷
关键词：
Nifuroxazide; STAT3; TNF-alpha; IL-18; Diabetes; JAK/STAT SIGNALING PATHWAY; OXIDATIVE STRESS; KAPPA-B; PREVENTS; TRANSDUCER; ACTIVATOR; DAMAGE; JANUS;
D O I：
10.1016/j.cbi.2017.12.030
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Diabetic nephropathy (DN) is a serious complication of diabetes mellitus. Moreover, it is amongst the most common causes of end-stage renal failure. Inflammation is a crucial player in both development and progression of DN. JAK2/STA3 is a pleotropic cascade reported to regulate diverse inflammatory events. Previous studies reported involvement of JAK2/STA3 signal transduction pathway in diabetes-associated renal injury. In the current study, the inhibitory effect of nifuroxazide (25 mg/kg/day, orally) against inflammatory condition associating diabetic kidney progression in rats was evaluated. The underlying hypothesis is mainly via the inhibitory effect of nifuroxazide on STAT3 signaling. Results revealed that nifuroxazide effectively inhibited STAT3 activation in diabetic male rats, improved glomerular filtration function, protected against diabetes-induced histopathological and ultramicroscopic structural alterations. Further, nifuroxazide treatment significantly reduced renal macrophage infiltration and fibrosis and decreased mRNA and protein levels of TNF-alpha and IL-18 in diabetic renal tissue. The current findings shed the light on nifuroxazide's efficacy as an alternative anti-inflammatory therapy to hinder the development and progression of DN in diabetic patients mainly via STAT3 inhibition.
引用
收藏
页码：111 / 120
页数：10
相关论文
共 47 条
[1]  
Alam Uazman, 2014, Handb Clin Neurol, V126, P211, DOI 10.1016/B978-0-444-53480-4.00015-1
[2]   Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats [J].
Anjaneyulu, M ;
Chopra, K .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (04) :244-248
[3]   Effects of Angiotensin Receptor Blocker on Oxidative Stress and Cardio-Renal Function in Streptozotocin-Induced Diabetic Rats [J].
Arozal, Wawaimuli ;
Watanabe, Kenichi ;
Veeraveedu, Punniyakoti Thanikachalam ;
Ma, Meilei ;
Thandavarayan, Rajarajan Amirthalingam ;
Suzuki, Kenji ;
Tachikawa, Hitoshi ;
Kodama, Makoto ;
Aizawa, Yoshifusa .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (08) :1411-1416
[4]   Enhanced Expression of Janus Kinase-Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy [J].
Berthier, Celine C. ;
Zhang, Hongyru ;
Schin, MaryLee ;
Henger, Anna ;
Nelson, Robert G. ;
Yee, Berne ;
Boucherot, Anissa ;
Neusser, Matthias A. ;
Cohen, Clemens D. ;
Carter-Su, Christin ;
Argetsinger, Lawrence S. ;
Rastaldi, Maria P. ;
Brosius, Frank C. ;
Kretzler, Matthias .
DIABETES, 2009, 58 (02) :469-477
[5]   JAK inhibition in the treatment of diabetic kidney disease [J].
Brosius, Frank C. ;
Tuttle, Katherine R. ;
Kretzler, Matthias .
DIABETOLOGIA, 2016, 59 (08) :1624-1627
[6]   Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting [J].
Cade, W. Todd .
PHYSICAL THERAPY, 2008, 88 (11) :1322-1335
[7]   Oleanolic acid prevents progression of streptozotocin induced diabetic nephropathy and protects renal microstructures in Sprague Dawley rats [J].
Dubey, Vishal K. ;
Patil, Chandragouda R. ;
Kamble, Sarika M. ;
Tidke, Priti S. ;
Patil, Kalpesh R. ;
Maniya, Pragnesh J. ;
Jadhav, Ramchandra B. ;
Patil, Sudha P. .
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2013, 4 (01) :47-52
[8]   Reno-protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1 [J].
Elsherbiny, Nehal M. ;
El Galil, Khaled H. Abd ;
Gabr, Mahmoud M. ;
Al-Gayyar, Mohammed M. ;
Eissa, Laila A. ;
El-Shishtawy, Mamdouh M. .
EUROPEAN CYTOKINE NETWORK, 2012, 23 (03) :78-86
[9]   Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib [J].
Elsherbiny, Nehal Mohsen ;
El-Sherbiny, Mohamed ;
Said, Eman .
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 2015, 71 (04) :635-648
[10]   Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? [J].
Gallagher, H. ;
Suckling, R. J. .
DIABETES OBESITY & METABOLISM, 2016, 18 (07) :641-647
12345